Behavioral Change consultant Dr. Kristina Curtis joins Jörn, Louise and Roger to discuss the unique challenges associated with weight loss through dieting and nutrition and ways government can support this effort.
This final conversation focuses on conference presentations on Determinants of MASH Health and the Healthy Livers, Healthy Lives program, and what panelists anticipate for #TLM2025.
This conversation focuses on two patient-related issues: the importance of patient advocacy in removing biopsy from clinical trial designs and more generally, principles for patient-centric clinical trials.
This conversation covers the likely role of FGF-21 agents in future MASH therapy and discusses positive messages from the “FDA Corner” session.
This conversation starts by asking whether approval of two drugs for use without biopsy will challenge MASH trial recruitment and goes on to look at recent studies discussing patient genotyping and clustering.
In the first conversation of our review of #TLM2024, panelists share general impressions and discuss the ESSENCE trial, semaglutide’s Phase 3 trial demonstrating regression of fibrosis.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key takeaways for his business from EASL Congress 2024.
In a conversation from May, 2023, patient advocates patient advocates Mike Betel, Tony Villiotti and Wayne Eskridge joined co-hosts Louise Campbell and Roger Green to share reactions to the Public Comments session of ICER’s report on MASH drugs obeticholic acid and resmetirom.
This week’s vault conversation looks back 17 months to the publication of revised AASLD Practice Guidance.
Co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the new MASLD Clinical Practice Guidelines from EASL, EASDand EASO.
